NASDAQ:MEDP - Medpace Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$56.83 -1.98 (-3.37 %)
(As of 03/22/2019 12:32 PM ET)
Previous Close$58.81
Today's Range$56.80 - $58.51
52-Week Range$33.52 - $71.66
Volume8,578 shs
Average Volume937,399 shs
Market Capitalization$2.03 billion
P/E Ratio21.98
Dividend YieldN/A
Beta1.61
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its clinical development services include medical affairs, clinical trial management, feasibility and start-up study, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.

Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEDP
CUSIPN/A
Phone513-579-9911

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$704.59 million
Cash Flow$3.5167 per share
Book Value$16.56 per share

Profitability

Net Income$73.18 million

Miscellaneous

Employees2,900
Market Cap$2.03 billion
Next Earnings Date4/29/2019 (Estimated)
OptionableOptionable

Medpace (NASDAQ:MEDP) Frequently Asked Questions

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

How were Medpace's earnings last quarter?

Medpace Holdings Inc (NASDAQ:MEDP) released its quarterly earnings data on Monday, February, 25th. The company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.07. The company earned $192.12 million during the quarter, compared to analyst estimates of $184.66 million. Medpace had a net margin of 11.27% and a return on equity of 17.66%. Medpace's revenue for the quarter was up 70.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.39 EPS. View Medpace's Earnings History.

When is Medpace's next earnings date?

Medpace is scheduled to release their next quarterly earnings announcement on Monday, April 29th 2019. View Earnings Estimates for Medpace.

What guidance has Medpace issued on next quarter's earnings?

Medpace updated its FY19 earnings guidance on Monday, February, 25th. The company provided earnings per share (EPS) guidance of $2.58-2.69 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.97. The company issued revenue guidance of $783-807 million, compared to the consensus revenue estimate of $799.26 million.Medpace also updated its FY 2019 guidance to $2.58-2.69 EPS.

What price target have analysts set for MEDP?

5 equities research analysts have issued 1-year target prices for Medpace's stock. Their forecasts range from $35.00 to $63.00. On average, they anticipate Medpace's stock price to reach $46.75 in the next twelve months. This suggests that the stock has a possible downside of 17.9%. View Analyst Price Targets for Medpace.

What is the consensus analysts' recommendation for Medpace?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medpace.

Has Medpace been receiving favorable news coverage?

News headlines about MEDP stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medpace earned a coverage optimism score of 0.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term.

Who are some of Medpace's key competitors?

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include EXACT Sciences (EXAS), NVIDIA (NVDA), BioTelemetry (BEAT), Micron Technology (MU), Alibaba Group (BABA), Square (SQ), Illumina (ILMN), Paypal (PYPL), ABIOMED (ABMD) and Gilead Sciences (GILD).

Who are Medpace's key executives?

Medpace's management team includes the folowing people:
  • Dr. August James Troendle, Chairman, Pres & CEO (Age 63)
  • Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 45)
  • Ms. Susan E. Burwig, Exec. VP of Operations (Age 56)
  • Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Todd Meyers, VP of Bus. Devel. & Marketing

When did Medpace IPO?

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are Medpace's major shareholders?

Medpace's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.68%), Pendal Group Ltd (4.48%), Acadian Asset Management LLC (3.81%), Bank of New York Mellon Corp (2.12%), Dimensional Fund Advisors LP (1.42%) and Dimensional Fund Advisors LP (1.42%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Medpace Limited Partnership. View Institutional Ownership Trends for Medpace.

Which major investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, D. E. Shaw & Co. Inc., Acadian Asset Management LLC, Bernzott Capital Advisors, Penserra Capital Management LLC, First Trust Advisors LP, Thrivent Financial for Lutherans and GSA Capital Partners LLP. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Medpace Limited Partnership. View Insider Buying and Selling for Medpace.

Which major investors are buying Medpace stock?

MEDP stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Pendal Group Ltd, Bank of New York Mellon Corp, PNC Financial Services Group Inc., Principal Financial Group Inc., Ranger Investment Management L.P., MERIAN GLOBAL INVESTORS UK Ltd and Gotham Asset Management LLC. View Insider Buying and Selling for Medpace.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $56.94.

How big of a company is Medpace?

Medpace has a market capitalization of $2.03 billion and generates $704.59 million in revenue each year. The company earns $73.18 million in net income (profit) each year or $2.59 on an earnings per share basis. Medpace employs 2,900 workers across the globe.

What is Medpace's official website?

The official website for Medpace is http://www.medpace.com.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]


MarketBeat Community Rating for Medpace (NASDAQ MEDP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  231 (Vote Outperform)
Underperform Votes:  211 (Vote Underperform)
Total Votes:  442
MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote "Outperform" if you believe MEDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel